Results 121 to 130 of about 23,301 (196)

Blastoid Mantle Cell Lymphoma in the Leukemic Phase: Resolving a Morphological Dilemma Through Flow Cytometry. [PDF]

Cureus
Kundu A, Giri S, Basu A.
europepmc   +1 more source

FOXM1 and NFκB Form a Positive Feedback Loop to Promote Cell Growth and Drug Resistance in Mantle Cell Lymphoma. [PDF]

Cells
Zhang Y, Song Y, Almowaled M, Shang C, Hua L, Sandhu I, Peters A, Chu MP, Wang P, Lai R.   +9 more
europepmc   +1 more source

Thrombotic microangiopathy associated with mantle cell lymphoma: a case report. [PDF]

BMC Nephrol
Tonouchi Y, Hashimoto K, Iwabuchi R, Sakai H, Nimura T, Yamaka K, Nishikawa M, Yamaguchi A, Sonoda K, Kamijo Y.   +9 more
europepmc   +1 more source

Single Cell RNA Transcriptomics of Mantle Cell Lymphoma Reveals the Presence of Treatment-Resistant Subclones at the Time of Diagnosis. [PDF]

Am J Hematol
Manakov D, Klanova M, Kolar M, Ivanek R, Geier F, Roux J, Zikmund T, Winkowska L, Kriegova E, Manakova J, Tuskova L, Spanikova S, Scasna A, Trneny M, Klener P.   +14 more
europepmc   +1 more source

Inhibition of CDC20 suppresses the development and progression of mantle cell lymphoma through PI3K/AKT pathway. [PDF]

Ann Hematol
Chen Y, Yang P, Gao S, Liu S, Wang J, Zhang W, Jing H.   +6 more
europepmc   +1 more source

EHA-EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma. [PDF]

Hemasphere
Jerkeman M, Aurer I, Campo E, Cheah CY, Clark J, Doorduijn J, Eyre TA, Fehr M, Giné E, Gomes da Silva M, Klener P, Ladetto M, Ribrag V, Shpilberg O, Walewski J, Dreyling M, EHA Guidelines Committee and the European MCL Network.   +16 more
europepmc   +1 more source

Inhibition of NAMPT targets DNA damage response to sensitize alkylating chemotherapy in TP53 mutant mantle cell lymphoma. [PDF]

Blood Adv
Li N, Liu Y, Zhang L, Guo S, Wu Z, Xu Y, Yang M, Kong J, Che Y, Shao K, Yang H.   +10 more
europepmc   +1 more source

Mantle cell lymphoma presenting primarily as cutaneous lesions: A case report. [PDF]

World J Clin Cases
Zhou PY, Chen W, Wang L.
europepmc   +1 more source

Inhibition of BIRC5 and MCL-1 as a potential treatment strategy to overcome drug resistance in Mantle Cell Lymphoma. [PDF]

Blood Cancer J
Pfitzer J, Chakravarti S, Mazumder S, Li F, Mukherjee UK, Mitra AK.   +5 more
europepmc   +1 more source

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy. [PDF]

Blood Cancer J
Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Danilov A, Argao C, Ruan J, Nizamuddin IA, Kahl BS, Grover NS, Khan NB, Pongas GN, Lossos IS, Ouchveridze E, Tun AM, Baidoun F, Alhaj Moustafa M, Harris ZI, Munoz JL, Young PR, Portell CA, Reagan PM, Ryan CE, Merryman RW, Velayati A, Greenwell IB, Gerber DG, Jain P, Wang ML, Ayyappan SR, Mou E, Banaszak LG, Pophali PA, Stack AC, Messmer MR, Narkhede MS, Mehta A, Moyo TK, Ghosh N, Bhansali RS, Barta SK, Kamdar MK, Anna J, Stanisic AV, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P.   +55 more
europepmc   +1 more source